Literature DB >> 32540930

Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.

Bolutife Fakoya1,2, Brandon Sit1,2, Matthew K Waldor3,2,4.   

Abstract

Current mouse models for evaluating the efficacy of live oral cholera vaccines (OCVs) have important limitations. Conventionally raised adult mice are resistant to intestinal colonization by Vibrio cholerae, but germfree mice can be colonized and have been used to study OCV immunogenicity. However, germfree animals have impaired immune systems and intestinal physiology; also, live OCVs colonize germfree mice for many months, which does not mimic the clearance kinetics of live OCVs in humans. In this study, we leveraged antibiotic-treated, conventionally raised adult mice to study the effects of transient intestinal colonization by a live OCV V. cholerae strain. In a single-dose vaccination regimen, we found that HaitiV, a live-attenuated OCV candidate, was cleared by streptomycin-treated adult mice within 2 weeks after oral inoculation. This transient colonization elicited far stronger adaptive immune correlates of protection against cholera than did inactivated whole-cell HaitiV. Infant mice from HaitiV-vaccinated dams were also significantly more protected from choleric disease than pups from inactivated-HaitiV-vaccinated dams. Our findings establish the benefits of antibiotic-treated mice for live-OCV studies as well as their limitations and underscore the immunogenicity of HaitiV.IMPORTANCE Oral cholera vaccines (OCVs) are being deployed to combat cholera, but current killed OCVs require multiple doses and show little efficacy in young children. Live OCVs have the potential to overcome these limitations, but small-animal models for testing OCVs have shortcomings. We used an antibiotic treatment protocol for conventional adult mice to study the effects of short-term colonization by a single dose of HaitiV, a live-OCV candidate. Vaccinated mice developed vibriocidal antibodies against V. cholerae and delivered pups that were resistant to cholera, whereas mice vaccinated with inactivated HaitiV did not. These findings demonstrate HaitiV's immunogenicity and suggest that this antibiotic treatment protocol will be useful for evaluating the efficacy of live OCVs.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  cholera; live vaccine; oral cholera vaccine; streptomycin

Mesh:

Substances:

Year:  2020        PMID: 32540930      PMCID: PMC7685556          DOI: 10.1128/JB.00232-20

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  30 in total

1.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

3.  Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.

Authors:  R Lagos; O San Martin; S S Wasserman; V Prado; G A Losonsky; C Bustamante; M M Levine
Journal:  Pediatr Infect Dis J       Date:  1999-07       Impact factor: 2.129

4.  Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.

Authors:  Firdausi Qadri; Mohammad Ali; Julia Lynch; Fahima Chowdhury; Ashraful Islam Khan; Thomas F Wierzba; Jean-Louis Excler; Amit Saha; Md Taufiqul Islam; Yasmin A Begum; Taufiqur R Bhuiyan; Farhana Khanam; Mohiul I Chowdhury; Iqbal Ansary Khan; Alamgir Kabir; Baizid Khoorshid Riaz; Afroza Akter; Arifuzzaman Khan; Muhammad Asaduzzaman; Deok Ryun Kim; Ashraf U Siddik; Nirod C Saha; Alejandro Cravioto; Ajit P Singh; John D Clemens
Journal:  Lancet Infect Dis       Date:  2018-03-14       Impact factor: 25.071

5.  Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.

Authors:  Dipika Sur; Anna Lena Lopez; Suman Kanungo; Allison Paisley; Byomkesh Manna; Mohammad Ali; Swapan K Niyogi; Jin Kyung Park; Banawarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Raman Rao; Thu Van Nguyen; Allan Donner; Nirmal K Ganguly; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens
Journal:  Lancet       Date:  2009-10-08       Impact factor: 79.321

6.  Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.

Authors:  Wilbur H Chen; Mitchell B Cohen; Beth D Kirkpatrick; Rebecca C Brady; David Galloway; Marc Gurwith; Robert H Hall; Robert A Kessler; Michael Lock; Douglas Haney; Caroline E Lyon; Marcela F Pasetti; Jakub K Simon; Flora Szabo; Sharon Tennant; Myron M Levine
Journal:  Clin Infect Dis       Date:  2016-03-21       Impact factor: 9.079

Review 7.  Mouse Microbiota Models: Comparing Germ-Free Mice and Antibiotics Treatment as Tools for Modifying Gut Bacteria.

Authors:  Elizabeth A Kennedy; Katherine Y King; Megan T Baldridge
Journal:  Front Physiol       Date:  2018-10-31       Impact factor: 4.566

8.  Anaerobic nitrate reduction divergently governs population expansion of the enteropathogen Vibrio cholerae.

Authors:  Emilio Bueno; Brandon Sit; Matthew K Waldor; Felipe Cava
Journal:  Nat Microbiol       Date:  2018-10-01       Impact factor: 17.745

Review 9.  Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis.

Authors:  Qifang Bi; Eva Ferreras; Lorenzo Pezzoli; Dominique Legros; Louise C Ivers; Kashmira Date; Firdausi Qadri; Laura Digilio; David A Sack; Mohammad Ali; Justin Lessler; Francisco J Luquero; Andrew S Azman
Journal:  Lancet Infect Dis       Date:  2017-07-17       Impact factor: 25.071

10.  Commensal-derived metabolites govern Vibrio cholerae pathogenesis in host intestine.

Authors:  Jin Sun You; Ji Hyun Yong; Gwang Hee Kim; Sungmin Moon; Ki Taek Nam; Ji Hwan Ryu; Mi Young Yoon; Sang Sun Yoon
Journal:  Microbiome       Date:  2019-09-14       Impact factor: 14.650

View more
  4 in total

1.  Dissecting serotype-specific contributions to live oral cholera vaccine efficacy.

Authors:  Brandon Sit; Bolutife Fakoya; Ting Zhang; Gabriel Billings; Matthew K Waldor
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

Review 2.  Animal models for dissecting Vibrio cholerae intestinal pathogenesis and immunity.

Authors:  Brandon Sit; Bolutife Fakoya; Matthew K Waldor
Journal:  Curr Opin Microbiol       Date:  2021-10-22       Impact factor: 7.934

3.  Nontoxigenic Vibrio cholerae Challenge Strains for Evaluating Vaccine Efficacy and Inferring Mechanisms of Protection.

Authors:  Bolutife Fakoya; Karthik Hullahalli; Daniel H F Rubin; Deborah R Leitner; Roma Chilengi; David A Sack; Matthew K Waldor
Journal:  mBio       Date:  2022-04-07       Impact factor: 7.786

Review 4.  The Interface of Vibrio cholerae and the Gut Microbiome.

Authors:  Jennifer Y Cho; Rui Liu; John C Macbeth; Ansel Hsiao
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.